1. Home
  2. Healthcare
  3. Geographic Atrophy Market Size, Share, Outlook 32

Geographic Atrophy Market Size, Share, Outlook 32

Geographic Atrophy Market Size and Forecast (2025 - 2032), By Stage (Early-Stage GA, Intermediate GA, Advanced GA), By Diagnostic Method (Fundus Autofluorescence, Optical Coherence Tomography, Fundus Photography, Fluorescein Angiography), By Treatment (Complement Inhibitors, Neuroprotective Agents, Visual Cycle Modulators, Gene Therapies), By End User (Hospitals, Eye Clinics, Ambulatory Surgical Centers), and Geography.

Report Code: HEA0095
Report Format: PDF + PPT + Excel
Download PDF Buy Now
Report Description

Report Highlights:

From USD 1.9 billion in 2022 to USD 3.8 billion by 2031, the worldwide Geographic Atrophy Market is expected to reach a high CAGR of 5.6% over the Forecast Period 2025-2032, North America is likely to control the market.

Rising incidence of age-related macular degeneration (AMD) and the global geriatric population are driving notable expansion of the Geographic Atrophy (GA) market. Given GA is the advanced form of dry AMD, the increasing prevalence of AMD directly affects the GA market. Further driving market growth are developments in diagnostic technology and the availability of new treatment choices. Furthermore helping to drive market expansion are growing knowledge of retinal disorders and better healthcare facilities in underdeveloped nations.


Market Dynamics:

Change in market trend towards focused therapeutics and tailored therapy for GA management

Targeting therapeutics and tailored therapy are driving a paradigm change in the GA industry. Advances in genomics and proteomics allow scientists to find certain biomarkers and genetic elements linked with GA development, hence driving this trend. Customized therapy options based on specific patient traits—including genetic profiles and illness stages—are under development by pharmaceutical firms. This tailored strategy seeks to reduce adverse effects and enhance therapeutic effectiveness. Furthermore improving the accuracy of GA management is the use of artificial intelligence and machine learning in diagnoses and treatment planning. Healthcare practitioners are therefore using these customized approaches more and more, which results in better patient outcomes and stimulates market development.


Market Motivator Increasing frequency of geographic atrophy and age-related macular degeneration

Main causes of market expansion include geographic atrophy and age-related macular degeneration (AMD), which are becoming more common. The prevalence of AMD and its advanced form, GA, is rising as the worldwide population ages. Recent epidemiological research estimate that GA affects around 5 million persons globally; in the next years, this figure is anticipated to rise dramatically. The progressive character of GA, which causes permanent visual loss, has made efficient therapies very urgently needed. From biotechnology businesses to pharmaceutical corporations, this increasing patient population has drawn significant research and development funding. Complement inhibitors, neuroprotective medicines, and gene therapies are among the new treatments developed in response to the possible market size and unmet medical requirements related with GA. Thus, the GA market is growing in response to the increasing patient pool and pressing need for therapeutic choices.


Restraints in the Market Early diagnostic challenges and few choices for advanced GA therapy

Early identification and the restricted therapy choices accessible for late stages of the illness are major limitations on the Geographic Atrophy market. Early on, GA frequently advances slowly and may stay asymptomatic; so, early identification is challenging. Lack of generally accessible, reasonably priced screening techniques for early-stage GA compromises timely intervention and care. Furthermore, even if studies are still in progress, there are not any FDA-approved medications especially for GA at now. The existing treatments mostly concentrate on slowing down the course of illness rather than restoring eyesight loss. Especially for advanced GA, this restriction in treatment choices might deter patient involvement and lower market potential. Moreover, the great expense connected with new treatments and the need of long-term maintenance create difficulties for market expansion especially in areas with low healthcare resources.


Segment Overview:

Treatment segment dominated by complement inhibitors

Leading therapy method in the Geographic Atrophy market is now complement inhibitors. Targeting the complement cascade a fundamental component of the immune system linked to GA pathogenesis—these medications Complement inhibitors help to lower inflammation and stop further damage to retinal cells. Promising clinical trial findings showing their ability to slow down GA development help to explain the predominance of this group. Many complement inhibitors are in late-stage clinical research; some demonstrate significant slowing down of GA lesion growth rates. With these treatments providing patients with a focused treatment choice for the first time, their projected acceptance will transform GA management. Significant expenditures from pharmaceutical firms and growing physician knowledge of the function of complement in GA help this industry to flourish even more.


Regional Outlook:

North America dominates the geographic atrophy market

Comprising the most market share, North America rules the Geographic Atrophy market. Geographic atrophy in the United States and Canada and high frequency of age-related macular degeneration define this regional leadership mostly. The area's market supremacy stems from its superior healthcare system, early acceptance of new treatments, and large research and development funding. Higher healthcare expenses and a well-established payment structure help North America as well, therefore enabling improved access to modern therapies. Leading research institutes and important market participants in the area help to stimulate invention and market expansion even further. Early diagnosis and intervention have also resulted from growing knowledge among patients and healthcare professionals regarding GA combined with proactive screening initiatives. These elements together rank North America as the leader in the worldwide Geographic Atrophy market, a trend likely to last the whole projected period.


Competitive Landscape:

Geographic Atrophy Market Competitive Landscape: Rapid innovation and great competitiveness define the Geographic Atrophy Market. Important stakeholders are emphasizing on creating new treatments, especially in relation to complement inhibition and neuroprotection. To improve their product ranges and market posture, big pharmaceutical corporations are aggressively seeking strategic alliances and acquisitions. Also making major contributions are emerging biotech companies introducing fresh ideas for GA therapy. With multiple possible treatments in late-stage development, continuous clinical research sharpens the competitive environment. To show long-term effectiveness and safety, companies are extensively spending on post-marketing research and real-world data collecting. Players are also stressing patient-centric strategies as the market develops, including the creation of less intrusive drug delivery systems and combination medicines. Constant improvements in GA treatment resulting from this dynamic environment help patients and help to shape the industry going forward.

 

Major Players:

  • Apellis Pharmaceuticals
  • Iveric Bio
  • Roche (Genentech)
  • Novartis
  • Regeneron Pharmaceuticals
  • AstraZeneca
  • Gyroscope Therapeutics
  • Gemini Therapeutics
  • Alkeus Pharmaceuticals
  • NGM Biopharmaceuticals
  • Allegro Ophthalmics
  • Lineage Cell Therapeutics
Table of Content

1. INTRODUCTION

   1.1. Market Definition

   1.2. Study Scope

   1.3. Currency Conversion

   1.4. Study Period (2025- 2032)

   1.5. Regional Coverage

2. RESEARCH METHODOLOGY

   2.1. Primary Research

   2.2. Secondary Research

   2.3. Company Share Analysis

   2.4. Data Triangulation

3. EXECUTIVE SUMMARY

   3.1. Global Geographic Atrophy Market (2025 – 2032)

   3.2. Global Geographic Atrophy Market (2025 – 2032)

      3.2.1. Market Segment By Stage (2025 – 2032)

      3.2.2. Market Segment By Diagnostic Method (2025 – 2032)

      3.2.3. Market Segment By Treatment (2025 – 2032)

      3.2.4. Market Segment By End User (2025 – 2032)

4. MARKET DYNAMICS

   4.1. Market Trends

      4.1.1. Shift towards personalized medicine and targeted therapies for GA management

      4.1.2. Advancements in imaging technologies for early GA detection

      4.1.3. Growing focus on combination therapies for enhanced efficacy

   4.2. Market Drivers

      4.2.1. Increasing prevalence of age-related macular degeneration and geographic atrophy

      4.2.2. Rising investments in R&D for novel GA treatments

      4.2.3. Growing awareness and improved diagnostic capabilities

   4.3. Market Restraints

      4.3.1. Challenges in early diagnosis and limited treatment options for advanced GA

      4.3.2. High cost of emerging therapies and reimbursement issues

   4.4. Porter's Five Forces Analysis

      4.4.1. Threat of New Entrants

      4.4.2. Bargaining Power of Buyers/Consumers

      4.4.3. Bargaining Power of Suppliers

      4.4.4. Threat of Substitute Products

      4.4.5. Intensity of Competitive Rivalry

   4.5. Supply Chain Analysis

   4.6. Pricing Analysis

   4.7. Regulatory Analysis

   4.8. Pipeline Analysis

5. BY STAGE (MARKET VALUE (US$ MILLION) – 2025-2032*)

   5.1. Early-Stage GA

   5.2. Intermediate GA

   5.3. Advanced GA

6. BY DIAGNOSTIC METHOD

   6.1. Fundus Autofluorescence

   6.2. Optical Coherence Tomography

   6.3. Fundus Photography

   6.4. Fluorescein Angiography

7. BY TREATMENT

   7.1. Complement Inhibitors

   7.2. Neuroprotective Agents

   7.3. Visual Cycle Modulators

   7.4. Gene Therapies

8. BY END USER

   8.1. Hospitals

   8.2. Eye Clinics

   8.3. Ambulatory Surgical Centers

9. GEOGRAPHY

   9.1. North America

      9.1.1. United States

      9.1.2. Canada

      9.1.3. Mexico

   9.2. South America

      9.2.1. Brazil

      9.2.2. Argentina

      9.2.3. Rest of South America

   9.3. Europe

      9.3.1. Germany

      9.3.2. United Kingdom 

      9.3.3. France

      9.3.4. Italy

      9.3.5. Spain

      9.3.6. Russia

      9.3.7. Rest of Europe

   9.4. Asia-Pacific

      9.4.1. China

      9.4.2. Japan

      9.4.3. India

      9.4.4. Australia

      9.4.5. South Korea

      9.4.6. Rest of Asia-Pacific

   9.5. Middle-East

      9.5.1. UAE

      9.5.2. Saudi Arabia

      9.5.3. Turkey

      9.5.4. Rest of Middle East

   9.6. Africa

      9.6.1. South Africa

      9.6.2. Egypt

      9.6.3. Rest of Africa

10. COMPETITVE LANDCAPE

    10.1. Key Developments

    10.2. Company Market Share Analysis

    10.3. Product Benchmarking

11. SWOT ANALYSIS

12. COMPANY PROFILES

    12.1. Apellis Pharmaceuticals

    12.2. Iveric Bio

    12.3. Roche (Genentech)

    12.4. Novartis

    12.5. Regeneron Pharmaceuticals

    12.6. AstraZeneca

    12.7. Gyroscope Therapeutics

    12.8. Gemini Therapeutics

    12.9. Alkeus Pharmaceuticals

    12.10. NGM Biopharmaceuticals

    12.11. Allegro Ophthalmics

    12.12. Lineage Cell Therapeutics (*LIST NOT EXHAUSTIVE)

13. MARKET OPPORTUNITIES

Scope of the Report

By Stage:

  • Early-Stage GA

  • Intermediate GA

  • Advanced GA

By Diagnostic Method:

  • Fundus Autofluorescence

  • Optical Coherence Tomography

  • Fundus Photography

  • Fluorescein Angiography

By Treatment:

  • Complement Inhibitors

  • Neuroprotective Agents

  • Visual Cycle Modulators

  • Gene Therapies

By End User:

  • Hospitals

  • Eye Clinics

  • Ambulatory Surgical Centers

Frequently Asked Questions

We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.

At aurorawaveintellects.com, we believe that every industry is important to us. Our extensive team of analysts give equal focus to various industries in order to cater to our client needs, some of them being – Healthcare & Pharma, Medical, Automotive, Electric, Chemical, Manufacturing, Energy & Power, Consumer Goods etc.
Our core expertise lies in gaining deeper insights from reliable and trusted voices in the market. We always analyse market trends over the course of multiple years and examine which topics are most relevant to our clients. We pay a great deal of attention to emerging trends, niche technologies, and the latest innovations and research to bring out the best that we can offer.
We understand that every client is different and so is their requirement. While we try to gauge our clients’ needs, we are unable to cover every possible angle of a market in an off-the-shelf report. Hence, we also provide customization options to our reports to suit your needs. If you would like to know what information we can provide about a particular topic, please get in touch with us at info@aurorawaveintellects.com.
Our Research Reports give insights into a gamut of qualitative and quantitative topics. Every Research Report contains the following: • Market landscape • Market size • Market segmentation • Market drivers, challenges, and trends • Vendor landscape For more detail on what a specific report contains, click on report details to know more. If you would like to know what information we can provide about a particular topic, please get in touch with us at info@aurorawaveintellects.com
Our Research Reports are frequently updated with new data and predictions. We also have reports from previous years for specific topics. If you need help, contact us at info@aurorawaveintellects.com and we will be happy to assist you for your query.

We at aurorawaveintellects.com offer mainly 3 types of licenses:

• Single User: Research Report copy can be distributed to a single user only

• Multi User: Research Report distribution is restricted up to 5 users.

• Corporate License :Research Report can be distributed across the company.

Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:

• PDF

• Word Document

• PPT

To purchase a research report, you can browse through various categories, industries or topics and choose a particular report. Next, choose a license type and add the report to your cart. Then simply check out and complete the payment transaction and your report will be delivered to your inbox via email..

Following modes are available for making the payment:

• Online Payment (Visa Card, Master Card, Stripe)

• Razorpay

• Net Banking

• Bank Wire Transfer

At Research Reports Inc., we believe in providing the best value and offering competitive pricing to our customers to reflect that value. However, if you would still like to find out about discounts and offers, please get in touch with us at info@aurorawaveintellects.com.
Yes, you can purchase individual sections of the report. Please get in touch with us at info@aurorawaveintellects.com with your specific request, and we will support you accordingly.
As soon as the purchase process is over and the payment transaction is complete, you will receive the receipt via email.
The purchased Research Report is delivered to your registered email address within 48 hours of receipt of payment. If in case you did not, please check your spam folder. If you still haven’t received it, please get in touch with us at info@aurorawaveintellects.com
If you would like to receive a hard copy of the report, please get in touch with us at info@aurorawaveintellects.com with details about your purchase and we will process the same.
At aurorawaveintellects.com, we offer strong after-sales support with every purchase. Feel free to call us or email us with your queries and we will ensure they are addressed appropriately.
The Research Reports we provide are designed to cater to all market participants across the value chain. However, we do understand that every report may or may not meet the exact client requirement. For any specific change or customization in the report, please get in touch with us at info@aurorawaveintellects.com with your specific request, and we will support you accordingly.

Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:

• Email: info@aurorawaveintellects.com

• United Kingdom: ++91 7382742511